InjectionClinical Overview
Caffeine Citrate is a central nervous system methylxanthine stimulant on the WHO Model List of Essential Medicines. It competitively antagonizes adenosine A1 and A2A receptors, stimulating respiratory drive in the medullary respiratory center, increasing sensitivity to hypercapnia, enhancing diaphragm contractility, and stimulating central inspiratory neuron activity. Indicated for the short-term treatment of apnea of prematurity in infants between 28 and < 33 weeks gestational age.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administered strictly in neonatal intensive care units (NICU) by slow intravenous infusion using a calibrated syringe infusion pump or orally by tube/feeds. Initial loading dose followed by daily maintenance dosing.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Tachycardia, restlessness, jitteriness, regurgitation, hyperglycemia, failure to thrive. Rare/Severe: Necrotizing enterocolitis (NEC), severe seizures, and cardiac arrhythmias.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Cardiopulmonary monitoring is mandatory during treatment. Monitor heart rate continuously; hold dose if heart rate exceeds 180 bpm. Use with caution in infants with seizure disorders or impaired renal/hepatic clearance.
Schedule H (Prescription Required - Neonatal Intensive Care Only)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.
Paracetamol 500mg + Caffeine 25mg Tablet
Paracetamol (500mg/650mg) and Caffeine (25mg/50mg) Tablets is an enhanced analgesic-antipyretic combination. Caffeine is a central nervous system methylxanthine stimulant and adenosine receptor antagonist; it constricts dilated cerebral blood vessels and accelerates gastrointestinal absorption of paracetamol, enhancing analgesic efficacy by approximately 30-40%. Indicated for acute relief of tension headaches, migraine attacks, fever, toothache, and musculoskeletal aches.
Paracetamol 650mg + Caffeine 50mg Tablets
Paracetamol (500mg/650mg) and Caffeine (25mg/50mg) Tablets is an enhanced analgesic-antipyretic combination. Caffeine is a central nervous system methylxanthine stimulant and adenosine receptor antagonist; it constricts dilated cerebral blood vessels and accelerates gastrointestinal absorption of paracetamol, enhancing analgesic efficacy by approximately 30-40%. Indicated for acute relief of tension headaches, migraine attacks, fever, toothache, and musculoskeletal aches.
Caffeine (30mg) + Diphenhydramine (25mg) + Paracetamol (500mg) + Phenylephrine (5mg) Tablets
Caffeine (30mg) + Diphenhydramine (25mg) + Paracetamol (500mg) + Phenylephrine (5mg) Tablets is an established pharmaceutical agent in the Respiratory & Allergy category on the PMBI National Formulary. Formulated to treat obstructive airway disease, cough, or allergic disorders according to verified pharmacopoeial standards.